Further understanding of the catalytic activity of DUBs, as well as of knowledge on their regulation and substrate specificity, will promote the development of DUB inhibitors as potential anti-cancer drugs. Several DUBs have been identified as driving forces that can trigger and/or enhance tumorigenic TGF-β/SMAD signaling. This evidence concerns the gene ZUP1 and cancer.